Cargando…
Development and characterization of single domain monoclonal antibody against programmed cell death ligand-1; as a cancer inhibitor candidate
OBJECTIVE(S): One of the important interactions in controlling the human immune system is the reaction between checkpoint proteins such as programmed cell death-1 (PD-1) and its ligand, PD-L1. These are negative immunoregulatory molecules that promote immune evasion of tumor cells. PD-L1 expression...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mashhad University of Medical Sciences
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148396/ https://www.ncbi.nlm.nih.gov/pubmed/35656179 http://dx.doi.org/10.22038/IJBMS.2022.62522.13834 |